Resilience has caught the eye of the Canadian government, which will invest $163M to boost mRNA production
Bob Nelsen’s Resilience, with a mission no less ambitious than rewriting the rules of drug manufacturing, has raced off to a quick lead with just a year of life under its belt. The Canadian government likes what it sees, and plans to cut a healthy check to boost Resilience’s Mississauga facility.
The Canadian Strategic Innovation Fund will spend $163 million will modernize and expand production capacity for new technologies such as mRNA, the key component of Pfizer/BioNTech and Moderna’s vaccine, at Resilience’s site. The expansion will add 205 new jobs in Mississauga at a 136,000-square-foot facility that currently provides fill-finish manufacturing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.